India’s key vaccine challenge is at home, not abroad
Delhi has resumed exports of COVID-19 vaccines but the domestic roll-out of jabs is behind schedule
You must be signed in to read this analysis
In this article
- Production surge
- Covishield, made by the Pune-based Serum Institute of India (SII)
- Covaxin, made by the Hyderabad-based Bharat Biotech (BB)
- Russia's Sputnik V
- Resuming shipments
- Vaccines on the horizon
What is this?
This article is from the Oxford Analytica Daily Brief, which analyses geopolitical, economic, social, business and industrial developments on a global and regional basis, providing clients with timely, authoritative analysis every business day of the year. Find out more about the Oxford Analytica Daily Brief, or request a trial.
